The C-C chemokine receptor type 2 (CCR2 or CKR2) is a G protein-coupled receptor (GPCR) primarily expressed on immune cells, including monocytes, macrophages, and T lymphocytes. It binds to chemokines such as CCL2 (MCP-1), CCL7. and CCL8. playing a critical role in mediating leukocyte migration to sites of inflammation or injury. CCR2 signaling is implicated in various inflammatory and autoimmune diseases, as well as cancer metastasis, due to its involvement in immune cell recruitment and activation. Antibodies targeting CCR2 are developed to block this pathway, offering potential therapeutic benefits. These antibodies can inhibit receptor-ligand interactions, thereby reducing immune cell infiltration and inflammation. In research, CCR2 antibodies are used as tools to study receptor function, cellular trafficking, and disease mechanisms. Therapeutic applications are explored in conditions like rheumatoid arthritis, atherosclerosis, multiple sclerosis, and cancer, though challenges remain in achieving specificity and minimizing off-target effects. Some preclinical and clinical trials highlight their potential, but further optimization is needed to address redundancy in chemokine signaling and improve efficacy.